Concordia’s int’l unit under U.K. Competition inquiry
THE U.K. Competition and Markets Authority (CMA) is investigating new issues in relation to the U.K. pharmaceutical sector, and that Concordia International Corp.’s international segment and certain of its products are part of the inquiry.
The investigation is at an early, information-gathering stage and the CMA has confirmed that, at this time, it has not reached any conclusions on whether competition law has been infringed.
The company commented, “We are working to better understand the CMA’s position and we will continue to work constructively to resolve these matters.”
The CMA’s investigation includes matters that predate Concordia’s ownership of the international segment. Concordia acquired the international segment as a result of its transaction to purchase Amdipharm Mercury Ltd., which closed on Oct. 21, 2015.
About Concordia International Corp.
Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. Going forward, the company is focused on becoming a leader in European specialty, off-patent medicines.
Concordia operates out of facilities in Oakville, Ont., and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England; and Mumbai, India.
We seek Safe Harbor.
Douglas Norman Deeth, Rochelle Fuhrmann, Itzhak Krinsky, Jordan M Kupinsky, Allan Oberman, Francis Perier, Patrick Vink
(CXR) Shares: 51,282,675